Sarepta Therapeutics Stock Today
| SRPT Stock | USD 73.45 6.52 8.15% |
PerformanceVery Weak
| Odds Of DistressVery Low
|
Sarepta Therapeutics is selling for under 73.45 as of the 21st of March 2025; that is 8.15 percent decrease since the beginning of the trading day. The stock's last reported lowest price was 73.45. Sarepta Therapeutics has a very small chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 21st of December 2024 and ending today, the 21st of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 3rd of June 1997 | Category Healthcare | Classification Health Care |
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts. The company has 97.03 M outstanding shares of which 4.92 M shares are at this time shorted by private and institutional investors with about 5.83 trading days to cover. More on Sarepta Therapeutics
Moving together with Sarepta Stock
Moving against Sarepta Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Sarepta Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO President | Douglas Esq | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, ARCA Biotechnology, NASDAQ Composite Total, SP Midcap 400, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsSarepta Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Sarepta Therapeutics' financial leverage. It provides some insight into what part of Sarepta Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sarepta Therapeutics (SRPT) is traded on NASDAQ Exchange in USA. It is located in 215 First Street, Cambridge, MA, United States, 02142 and employs 1,372 people. Sarepta Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 7.76 B. Sarepta Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 97.03 M outstanding shares of which 4.92 M shares are at this time shorted by private and institutional investors with about 5.83 trading days to cover.
Sarepta Therapeutics currently holds about 2.07 B in cash with (205.79 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 23.61.
Check Sarepta Therapeutics Probability Of Bankruptcy
Ownership AllocationSarepta Therapeutics shows a total of 97.03 Million outstanding shares. The majority of Sarepta Therapeutics outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Sarepta Therapeutics to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Sarepta Therapeutics. Please pay attention to any change in the institutional holdings of Sarepta Therapeutics as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Sarepta Ownership Details
Sarepta Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Geode Capital Management, Llc | 2024-12-31 | 1.7 M | |
| Deutsche Bank Ag | 2024-12-31 | 1.7 M | |
| Ubs Group Ag | 2024-12-31 | 1.5 M | |
| Groupama Asset Management | 2024-12-31 | 1.3 M | |
| Casdin Capital, Llc | 2024-12-31 | 1.1 M | |
| Pictet Asset Manangement Sa | 2024-12-31 | 1 M | |
| Norges Bank | 2024-12-31 | 1 M | |
| Camber Capital Management Llc | 2024-12-31 | 1000 K | |
| Morgan Stanley - Brokerage Accounts | 2024-12-31 | 991.7 K | |
| Blackrock Inc | 2024-12-31 | 11.2 M | |
| Vanguard Group Inc | 2024-12-31 | 9.1 M |
Sarepta Therapeutics Historical Income Statement
Sarepta Stock Against Markets
Sarepta Therapeutics Corporate Management
| Ryan JD | General VP | Profile | |
| Will Tilton | Head VP | Profile | |
| Joseph Bratica | Controller VP | Profile | |
| William Ciambrone | Ex Operations | Profile | |
| Dallan Murray | Executive Officer | Profile |
Additional Tools for Sarepta Stock Analysis
When running Sarepta Therapeutics' price analysis, check to measure Sarepta Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sarepta Therapeutics is operating at the current time. Most of Sarepta Therapeutics' value examination focuses on studying past and present price action to predict the probability of Sarepta Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sarepta Therapeutics' price. Additionally, you may evaluate how the addition of Sarepta Therapeutics to your portfolios can decrease your overall portfolio volatility.